Extract from the above information

It has antithrombin III (ATⅢ)-dependent anti-factor Xa activity, inhibits the formation of thrombi in vivo and in vitro, arterial and venous thrombi, and can stimulate endothelial cells to release tissue factor coagulation pathway inhibitor and plasminogen activator. It does not act as a thrombolytic drug but has an indirect synergistic effect on thrombolytic drugs. When producing antithrombotic effects, the possibility of bleeding is small, it has no mutagenic effect and does not affect reproductive function and embryonic development.

It has antithrombin III (ATⅢ)-dependent anti-factor Xa activity, and can inhibit the formation of thrombi in vivo and in vitro, and arterial and venous thrombi; it can stimulate endothelial cells to release tissue factor coagulation pathway inhibitor and plasminogen activator; it does not act as a thrombolytic drug, but has an indirect synergistic effect on thrombolytic drugs; when it produces an antithrombotic effect, the possibility of bleeding is small; it has no mutagenic effect and does not affect reproductive function and embryonic development.

One of the main cytokines that regulates granulocyte hematopoiesis in the bone marrow, selectively acts on granulocyte hematopoietic progenitor cells, promotes their proliferation and differentiation, and increases the function of terminally differentiated granulocyte cells

This product is human granulocyte colony-stimulating factor (rhGCSF) produced by genetic recombination technology. It is one of the main cytokines regulating granulocyte hematopoiesis in the bone marrow. It selectively acts on granulocyte hematopoietic progenitor cells, promotes their proliferation and differentiation, and can increase the function of terminally differentiated granulocyte cells.